FDA Hosts AdComm Meeting on Investigational SRP-9001 DMD Treatment

Published Date: 26 Mar 2023

The FDA has decided to hold an advisory committee meeting before May 29, 2023, the official date of Sarepta's investigational DMD drug SRP-9001 (also known as delandistrogen moxaparvovec).

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Studies have shown that physical activity prevents cancer in patients who have been treated for cancer in the past.

2.

New policy review highlights the importance of health-related quality of life in advanced cancer

3.

In myelofibrosis, combinations of rufolitinib reduce spleen volume.

4.

Better treatments buoy multiple-myeloma patients, bound by research cuts and racial disparities

5.

More Data from Population-Based Studies Show CRC Screening Lowers Cancer Death Risk.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot